Ageas will report its 2Q11 earnings on 24 August, before market. We expect a net profit of € 37m. Earnings compare unfavourable to 2Q10 when Ageas recorded a large reversal of deferred tax assets following the liquidation of Brussels S.A.. We also pencilled in € 384m gross impairments on Ageas’s Greek sovereign debt investment which after burden sharing with policyholders (50%), minorities (20%) and taxes, should see a net impact of € 103m.
The insurance activities should report a € 6.1m net profit o/w € -4.2m from Belgium, € -4.9m from the UK, € -0.8m from (46,42 EUR, -5,97%) Europe and € 16.0m from Asia. The life activities should contribute € 12.1m to insurance net profit driven by good commercial activity largely offset by impairments. The non-life activities should contribute € -11.7m as the improvement in combined ratio is most likely more than offset by Greek sovereign debt impairments. Other insurance should contribute € 5.0.
The general account should report a € 30.8m net profit including a € 18m revaluation of the (33,07 EUR, -3,33%) call, and a € -23m revaluation of the Relative Performance Notes. The decline in interest rates in 2Q11 probable also resulted in a positive revaluation of Royal Park Investments (€ 31.9m) as part of the variable rate assets were swapped into fixed rate and the portfolio has a positive carry.
2Q11 gross inflows are expected to have risen by 15.5% to € 5.35bn driven by the combined effect of rate rises in non-life, good commercial activity and changes in the scope.
Shareholders’ equity at 30 June is estimated at € 7.5bn, virtually flat compared to 1Q11.
Ageas’s valuation remains undemanding but the strong decline in market valuations (EV multiples and share at year low) prompt us to lower our target price to € 2.85. We remain Buying the share.